Skip to content

Comparing Fast vs. Slow Vitamin D Treatment in Osteoporosis Patients

The Effectiveness of Rapid correction versus Gradual correction in cases of vitamin D deficient Osteoporotic patients- A Randomized Control Trial. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/12/099176
Enrollment
76
Registered
2025-12-16
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M80-M85- Disorders of bone density and structure

Interventions

Intervention1: High dose vitamin D: The treatment group will receive the same regimen as the control group, along with daily high-dose vitamin D of 60,000IU supplementation for initial 5 days as a co

Sponsors

AIIMS
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.All patients who had given consent for the study. 2.Patients of age between more than 50 years with osteoporosis (T score less than -2.5 SD) as determined by DEXA scan. 3.Patients with normal Sr Creatinine, Sr Calcium, Sr Phosphate, Sr Alkaline Phosphatase.

Exclusion criteria

Exclusion criteria: 1. Secondary osteoporosis due to utilization of drugs like phenytoin, warfarin, corticosteroids etc and disuse osteoporosis due to deformity or stiffness or patients with endocrinological disorders causing osteoporosis. 2. Patients with abnormally high Sr Parathyroid levels with hypercalcemia ( primary hyperparathyroidism causes - secondary osteoporosis) 3. Subjects with vitamin D level more than 30ng/dL. 4. HIV patients using ART. 5. Patients with active tuberculosis or patients on anti-tubercular treatment. 6. Renal Failure patients on dialysis or post transplantation or patients with high serum creatinine. 7. Subjects with history of nephrolithiasis, urolithiasis. 8. Elderly women using hormone replacement therapy. 9. Elderly men using testosterone inhibitors for BPH. 10. Patients with sarcoidosis or malignancies or chemotherapy. 11. Alcoholic liver disease or any other significant liver disease with elevated enzymes. 12. Malabsorption syndromes. 13. Rheumatological disorders on DMARDs.

Design outcomes

Primary

MeasureTime frame
Change in T-score on DEXA scan of right hip from baseline to 6 months. Change in serum 25-hydroxy Vitamin D levels from baseline to 6 months. Proportion of patients achieving Vitamin D sufficiency at 6 months.Timepoint: Baseline and 6 months

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactS Kavin Balaji

AIIMS

maheshwar.ortho@gmail.com9440634372

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026